Active Pharmaceutical Ingredient API News and Research

RSS

AMRI announces fourth-quarter and full-year 2009 results

AMRI today reported financial and operating results for the fourth quarter and full year ending December 31, 2009.

8 Feb 2010

Pharma IQ to organize 4th Improving Solubility conference at The Park Hyatt in Philadelphia

Organized by Pharma IQ, a division of IQPC, the 4th Improving Solubility conference will be held March 29-31, 2010 at The Park Hyatt in Philadelphia, PA. This forum brings together pharmaceutical researchers and scientists to uncover advances in enhancing solubility, amorphous forms, bioavailability & lipid-based formulation of drugs.

From IQPC Ltd 5 Feb 2010

Javelin Pharmaceuticals' NDA for Dyloject Injection accepted for formal review

Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, has been accepted for formal review.

2 Feb 2010

Watson Pharmaceuticals provides detailed overview of its global operations at Investor Day meeting in NY

Watson Pharmaceuticals, Inc. today provided a detailed overview of its expanded global operations, enhanced supply chain capabilities and commercial and pipeline developments in its Brand and Generics businesses during an Investor Day meeting held in New York, NY.

22 Jan 2010

Medicity reports 91 percent increase in HIE technology bookings in 2009

Medicity – the leading provider of health information exchange (HIE) technology that empowers physicians, hospitals and communities with solutions to improve care collaboration – today reported a sharp, 91 percent increase in bookings in 2009 over the previous year and a 35 percent increase in five-year revenue backlog.

19 Jan 2010

Sirnaomics certifies polypeptide nanoparticle technology

Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has licensed a polypeptide nanoparticle technology invented by Professor A. James Mixson of University of Maryland Medical School.

18 Jan 2010

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Vertex Pharmaceuticals Incorporated today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also discussed recent progress in its lead development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF) and outlined proof-of-concept clinical trials planned in other serious diseases for 2010.

11 Jan 2010

Savient Pharmaceuticals announces filing of KRYSTEXXA BLA resubmission on track

Savient Pharmaceuticals, Inc. provided an update on its activities directed toward the resubmission of its Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy and reaffirmed its belief that it continues to be on track for the filing of the BLA resubmission for KRYSTEXXA in the first quarter of 2010.

9 Jan 2010

Particle Sciences to acquire HORIBA's Raman/Particle Characterization System

Particle Sciences Inc., a leading pharmaceutical CRO, is adding to its formulation and characterization abilities through a cooperative agreement with HORIBA Scientific. Under the agreement Particle Sciences will acquire a HORIBA Raman/Particle Characterization System.

7 Jan 2010

Vignet releases Connected Health Services platform infrastructure for mHealth devices and services

Vignet Inc., today announced its Connected Health Services platform infrastructure for mobile health (mHealth) devices and services. The new “person-centered” platform allows users to capture, aggregate, analyze and share data with their mobile devices, leveraging any wired or wireless interface, such as Bluetooth, ZigBee, Bluetooth LE and USB.

7 Jan 2010

AlphaRx, Venturepharm sign supply agreement for ARX1088's API

AlphaRx Inc. announced today that it has signed an agreement that provides long-term supply of the active pharmaceutical ingredient (API) for ARX1088, an orally active interferon inducer intended for the adjunctive treatment of Hepatitis in China and other emerging markets. Under the agreement, Venturepharm will be the primary supplier of AlphaRx's worldwide requirements for the compound.

17 Dec 2009

Hospira to acquire Orchid's pharmaceuticals business for $400 million

Hospira, Inc., the world leader in generic injectable pharmaceuticals, and Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company and among the top-five generic beta-lactam antibiotics manufacturers globally, today announced an agreement for Hospira to acquire Orchid's generic injectable finished-dosage form pharmaceuticals business for approximately $400 million.

15 Dec 2009

Study describing solid-state characterization of three forms of finasteride published

Aptuit, Inc. today announced the publication of new research in the December issue of the European Journal of Pharmaceutical Sciences, the official journal of the European Federation for Pharmaceutical Sciences (EUFEPS), which describes the solid-state characterization of three forms of finasteride.

11 Dec 2009

Francisco Partners to acquire QuadraMed

QuadraMed® Corporation, a leading provider of healthcare information technologies and services that help turn quality care into positive financial outcomes, announced that it has entered into a definitive merger agreement to be acquired by Francisco Partners, one of the world’s largest technology-focused private equity firms.

8 Dec 2009

Watson Pharmaceuticals obtains FTC approval to acquire Arrow Group

Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the Federal Trade Commission (FTC) has accepted a proposed consent order for public comment relating to Watson's pending acquisition of privately held Arrow Group and has granted early termination of the Hart Scott Rodino waiting period, thereby permitting the parties to close the transaction.

3 Dec 2009

Javelin Pharmaceuticals submits an NDA for Dyloject Injection

Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, for the management of acute moderate-to-severe pain in adults.

2 Dec 2009

Gentium announces financial results for the third quarter ended September 30, 2009

Gentium S.p.A. today reported financial results for the quarter ended September 30, 2009.

30 Nov 2009

OmniComm Systems chosen as Beardsworth's preferred EDC provider

OmniComm Systems, Inc., one of the fastest growing companies in the EDC marketplace, today announced that Beardsworth, a full service contract research organization (CRO) who specializes in difficult therapeutic areas, has selected OmniComm's TrialMaster EDC solution for conducting a Phase II vaccine study.

24 Nov 2009

AmKor and Hengdian Group sign license agreement to develop and market new drug candidate in China

AmKor (AmKor Pharma, Inc.) and Hengdian Group (Hengdian Group Ltd) today announced the signing of licensing agreement for further development and commercialization of Neu2000 in China.

24 Nov 2009

Experts to discuss the patented chemical imaging technology at DDL 20 meeting

In today's fast growing inhalables market, the availability of suitable, efficient and cost-effective means of gathering particle analysis data for pulmonary formulation is clear. At this year's Drug Delivery to the Lungs 20 (DDL 20) meeting, experts from ChemImage Corporation, will be on hand to discuss our patented chemical imaging technology and how ingredient-specific particle sizing (ISPS) fulfils precisely this requirement for drug particle size data.

23 Nov 2009